Regeneron to get payments from French company
-
- August
- 5
Eastview-based Regeneron Pharmaceuticals Inc., which is seeking to develop drugs for cancer, eye conditions and inflammatory conditions, said this morning it will receive at least $4.3 million a year for five years by allowing a French company to use its technology.
Sanofi-aventis SA will use Regeneron’s proprietary VelociGene technology in its internal research programs, Regeneron said. The technology provides models of gene function and disease.
Regeneron lost $105.6 million on revenue of $125.02 million in fiscal 2007.
This entry was posted
on Tuesday, August 5th, 2008 at 9:07 am by Allan Drury.
You can follow any responses to this entry through the RSS 2.0 feed.
Category: Biopharmaceutical
Print
| 
Email
